However, 20%–60% of patients do not respond to anti-VEGF therapies completely with some syndromes, such as persistent disease activity (PDA), which is characterized as persistent fluid exudation, unresolved or new hemorrhage, and/or progressive lesion fibrosis, as well as suboptimal vision recovery (SVR), which is defined as a failure to achieve functional visual acuity of 20/40 or better [7–11]. Here, VEGFA is linked to Patent ductus arteriosus.